| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 18 | 2024 | 1385 | 2.470 |
Why?
|
| Endometrial Hyperplasia | 6 | 2024 | 122 | 2.090 |
Why?
|
| Intrauterine Devices, Medicated | 2 | 2024 | 38 | 1.650 |
Why?
|
| Levonorgestrel | 2 | 2024 | 53 | 1.640 |
Why?
|
| NF-E2-Related Factor 2 | 10 | 2009 | 256 | 1.330 |
Why?
|
| Metformin | 7 | 2019 | 393 | 1.050 |
Why?
|
| Oleanolic Acid | 9 | 2009 | 111 | 0.980 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2020 | 327 | 0.980 |
Why?
|
| Self Concept | 1 | 2022 | 198 | 0.750 |
Why?
|
| Everolimus | 3 | 2021 | 436 | 0.710 |
Why?
|
| Obesity | 6 | 2023 | 2904 | 0.700 |
Why?
|
| Premenopause | 1 | 2020 | 136 | 0.700 |
Why?
|
| Students | 1 | 2022 | 333 | 0.690 |
Why?
|
| Imidazoles | 9 | 2009 | 1065 | 0.620 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 42 | 0.600 |
Why?
|
| Preventive Medicine | 1 | 2018 | 32 | 0.600 |
Why?
|
| Drug Delivery Systems | 2 | 2021 | 661 | 0.590 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2017 | 481 | 0.580 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 74 | 0.570 |
Why?
|
| Microbiota | 1 | 2023 | 547 | 0.570 |
Why?
|
| Microsatellite Instability | 3 | 2023 | 408 | 0.570 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 1059 | 0.550 |
Why?
|
| Professional Competence | 1 | 2018 | 139 | 0.550 |
Why?
|
| Estrogens | 1 | 2020 | 805 | 0.540 |
Why?
|
| Endometrium | 5 | 2020 | 457 | 0.540 |
Why?
|
| Research Personnel | 1 | 2018 | 167 | 0.530 |
Why?
|
| Anticarcinogenic Agents | 3 | 2007 | 368 | 0.530 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2020 | 1470 | 0.380 |
Why?
|
| Triterpenes | 2 | 2007 | 68 | 0.350 |
Why?
|
| Cytoskeletal Proteins | 2 | 2009 | 522 | 0.340 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2011 | 155 | 0.340 |
Why?
|
| Medical Oncology | 1 | 2018 | 1465 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2014 | 1281 | 0.320 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 322 | 0.310 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 397 | 0.310 |
Why?
|
| Aflatoxins | 1 | 2007 | 14 | 0.300 |
Why?
|
| Heterozygote | 1 | 2011 | 1056 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 10400 | 0.290 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 3707 | 0.280 |
Why?
|
| Hypoglycemic Agents | 3 | 2016 | 599 | 0.280 |
Why?
|
| Liver | 6 | 2009 | 3086 | 0.260 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2006 | 191 | 0.250 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 4795 | 0.240 |
Why?
|
| Biomarkers | 4 | 2020 | 5051 | 0.240 |
Why?
|
| Drug Design | 1 | 2007 | 372 | 0.240 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 4 | 2009 | 118 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 2399 | 0.230 |
Why?
|
| DNA Mismatch Repair | 3 | 2023 | 283 | 0.220 |
Why?
|
| Female | 29 | 2024 | 148940 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 9042 | 0.220 |
Why?
|
| Achievement | 1 | 2022 | 40 | 0.210 |
Why?
|
| Signal Transduction | 5 | 2013 | 12103 | 0.200 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 10708 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2020 | 2232 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2008 | 2453 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 103 | 0.190 |
Why?
|
| Humans | 31 | 2024 | 270740 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2023 | 232 | 0.190 |
Why?
|
| Ki-67 Antigen | 2 | 2020 | 675 | 0.180 |
Why?
|
| Antioxidants | 3 | 2009 | 521 | 0.180 |
Why?
|
| Rats | 5 | 2021 | 6441 | 0.180 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 84 | 0.180 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 274 | 0.180 |
Why?
|
| Polymers | 1 | 2021 | 222 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 382 | 0.170 |
Why?
|
| Progestins | 1 | 2020 | 92 | 0.170 |
Why?
|
| Cyclopentanes | 1 | 2020 | 42 | 0.170 |
Why?
|
| Microsatellite Repeats | 2 | 2023 | 627 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14617 | 0.170 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2019 | 37 | 0.170 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3035 | 0.160 |
Why?
|
| Animals | 21 | 2022 | 61956 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 965 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2024 | 13414 | 0.160 |
Why?
|
| Mutation | 6 | 2020 | 15912 | 0.160 |
Why?
|
| Middle Aged | 11 | 2024 | 90352 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 444 | 0.140 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2017 | 46 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 1710 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 659 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2023 | 1033 | 0.140 |
Why?
|
| Neoplasms | 2 | 2018 | 15927 | 0.140 |
Why?
|
| Adult | 10 | 2024 | 82040 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 854 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 904 | 0.140 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 725 | 0.140 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2017 | 161 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2021 | 2069 | 0.140 |
Why?
|
| Uterus | 1 | 2021 | 798 | 0.130 |
Why?
|
| Health Services Research | 1 | 2018 | 237 | 0.130 |
Why?
|
| Adiposity | 1 | 2018 | 238 | 0.130 |
Why?
|
| Proteome | 1 | 2020 | 571 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 272 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 306 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 5149 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 4130 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 1823 | 0.130 |
Why?
|
| Public Health | 1 | 2018 | 296 | 0.130 |
Why?
|
| Gene Expression | 3 | 2020 | 3640 | 0.130 |
Why?
|
| Estradiol | 3 | 2017 | 827 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 499 | 0.120 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2015 | 24 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 1336 | 0.120 |
Why?
|
| Body Composition | 1 | 2018 | 606 | 0.120 |
Why?
|
| Salpingectomy | 1 | 2015 | 46 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 2175 | 0.120 |
Why?
|
| Aged | 7 | 2024 | 73333 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2016 | 1012 | 0.110 |
Why?
|
| Body Weight | 2 | 2016 | 1307 | 0.110 |
Why?
|
| Weight Loss | 1 | 2018 | 628 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 4821 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1424 | 0.110 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2013 | 49 | 0.110 |
Why?
|
| Contraceptives, Oral | 1 | 2013 | 57 | 0.110 |
Why?
|
| Streptozocin | 1 | 2013 | 70 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 1402 | 0.110 |
Why?
|
| Hyperinsulinism | 1 | 2013 | 86 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 692 | 0.100 |
Why?
|
| Genomics | 1 | 2023 | 2835 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2610 | 0.100 |
Why?
|
| Mice | 14 | 2022 | 35600 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 3409 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2020 | 3669 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 15218 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2020 | 2928 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2014 | 6390 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2018 | 801 | 0.090 |
Why?
|
| Sirolimus | 1 | 2015 | 831 | 0.090 |
Why?
|
| Triazoles | 1 | 2015 | 627 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4492 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 517 | 0.090 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 2 | 2008 | 59 | 0.090 |
Why?
|
| Aflatoxin B1 | 2 | 2008 | 8 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2020 | 9470 | 0.090 |
Why?
|
| Nitriles | 1 | 2015 | 939 | 0.090 |
Why?
|
| Rats, Inbred F344 | 2 | 2008 | 239 | 0.080 |
Why?
|
| Anti-Obesity Agents | 1 | 2009 | 33 | 0.080 |
Why?
|
| Macaca | 1 | 2009 | 88 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2020 | 33737 | 0.080 |
Why?
|
| ras Proteins | 1 | 2013 | 804 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 1655 | 0.080 |
Why?
|
| DNA Adducts | 2 | 2008 | 213 | 0.080 |
Why?
|
| Chickens | 1 | 2009 | 783 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2008 | 1608 | 0.080 |
Why?
|
| Smoke | 1 | 2008 | 61 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 92 | 0.080 |
Why?
|
| Phenanthrenes | 1 | 2008 | 43 | 0.080 |
Why?
|
| Risk Factors | 3 | 2020 | 17888 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 841 | 0.070 |
Why?
|
| Thiocyanates | 1 | 2007 | 18 | 0.070 |
Why?
|
| Gelatin | 1 | 2007 | 43 | 0.070 |
Why?
|
| Thiones | 1 | 2007 | 19 | 0.070 |
Why?
|
| Sulfoxides | 1 | 2007 | 22 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2009 | 341 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2008 | 262 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 4223 | 0.070 |
Why?
|
| Antioxidant Response Elements | 1 | 2007 | 2 | 0.070 |
Why?
|
| Isothiocyanates | 1 | 2007 | 44 | 0.070 |
Why?
|
| ortho-Aminobenzoates | 1 | 2007 | 20 | 0.070 |
Why?
|
| Hyperoxia | 1 | 2009 | 138 | 0.070 |
Why?
|
| Aminopeptidases | 1 | 2007 | 33 | 0.070 |
Why?
|
| NADPH Dehydrogenase | 1 | 2007 | 9 | 0.070 |
Why?
|
| Pulmonary Emphysema | 1 | 2008 | 159 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2020 | 3557 | 0.070 |
Why?
|
| Lead | 1 | 2007 | 44 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2007 | 187 | 0.070 |
Why?
|
| Oxidative Stress | 3 | 2009 | 1149 | 0.070 |
Why?
|
| Phenols | 1 | 2007 | 105 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2009 | 5728 | 0.070 |
Why?
|
| Apoptosis | 5 | 2016 | 7757 | 0.070 |
Why?
|
| Texas | 1 | 2018 | 6449 | 0.070 |
Why?
|
| Thiophenes | 1 | 2007 | 147 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4958 | 0.070 |
Why?
|
| Serine Endopeptidases | 1 | 2007 | 275 | 0.070 |
Why?
|
| Metalloendopeptidases | 1 | 2007 | 176 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 201 | 0.070 |
Why?
|
| Response Elements | 1 | 2007 | 192 | 0.070 |
Why?
|
| Inactivation, Metabolic | 1 | 2006 | 42 | 0.070 |
Why?
|
| Hepatocytes | 1 | 2008 | 336 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4761 | 0.070 |
Why?
|
| Cytokines | 3 | 2016 | 2825 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 476 | 0.060 |
Why?
|
| Chemokines | 1 | 2006 | 290 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 30998 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2007 | 251 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 266 | 0.060 |
Why?
|
| Urea | 1 | 2006 | 304 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 1101 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 7914 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5595 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 14012 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2007 | 820 | 0.060 |
Why?
|
| Pyrazines | 1 | 2007 | 510 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 7381 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 7655 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2617 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 859 | 0.060 |
Why?
|
| Cell Proliferation | 5 | 2016 | 7238 | 0.060 |
Why?
|
| Rats, Zucker | 2 | 2014 | 59 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2471 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 1111 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2008 | 724 | 0.050 |
Why?
|
| Plasmalogens | 1 | 2002 | 7 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 678 | 0.050 |
Why?
|
| Neutrophils | 1 | 2006 | 873 | 0.050 |
Why?
|
| Transglutaminases | 1 | 2002 | 97 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 3597 | 0.050 |
Why?
|
| Young Adult | 1 | 2020 | 22251 | 0.050 |
Why?
|
| Phospholipids | 1 | 2002 | 167 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2002 | 212 | 0.050 |
Why?
|
| Hydrogels | 1 | 2002 | 134 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2007 | 1580 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2024 | 654 | 0.040 |
Why?
|
| Structure-Activity Relationship | 3 | 2007 | 979 | 0.040 |
Why?
|
| NEDD8 Protein | 1 | 2020 | 23 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2017 | 1604 | 0.040 |
Why?
|
| Liposomes | 1 | 2002 | 704 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2019 | 80 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2022 | 9292 | 0.040 |
Why?
|
| Pyridines | 1 | 2006 | 1313 | 0.040 |
Why?
|
| Disease Progression | 1 | 2011 | 6867 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2020 | 354 | 0.040 |
Why?
|
| Insulin | 2 | 2016 | 1483 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 377 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 1942 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 5056 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3917 | 0.040 |
Why?
|
| Kinetics | 3 | 2007 | 2220 | 0.040 |
Why?
|
| Male | 6 | 2022 | 128315 | 0.040 |
Why?
|
| Fertility | 1 | 2020 | 336 | 0.040 |
Why?
|
| Models, Molecular | 3 | 2007 | 1741 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2008 | 4116 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1933 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2019 | 683 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 3844 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 14849 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 148 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2008 | 526 | 0.030 |
Why?
|
| Adiponectin | 1 | 2016 | 143 | 0.030 |
Why?
|
| Calcium | 1 | 2002 | 1578 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 232 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 274 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 474 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 318 | 0.030 |
Why?
|
| Leptin | 1 | 2016 | 306 | 0.030 |
Why?
|
| Nitric Oxide | 2 | 2008 | 658 | 0.030 |
Why?
|
| Pyridones | 1 | 2017 | 360 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 4961 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 402 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 631 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 208 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 249 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1097 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2013 | 206 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 179 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 885 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2013 | 208 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 2008 | 1005 | 0.030 |
Why?
|
| Endometriosis | 1 | 2015 | 231 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2013 | 407 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2013 | 564 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 1138 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 737 | 0.020 |
Why?
|
| beta Catenin | 1 | 2015 | 683 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1189 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4960 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 827 | 0.020 |
Why?
|
| Transcriptome | 1 | 2019 | 1963 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2015 | 1060 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 244 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 2357 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 438 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2315 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 7100 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 22505 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 16689 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2008 | 63 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2008 | 57 | 0.020 |
Why?
|
| Aconitate Hydratase | 1 | 2008 | 17 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1432 | 0.020 |
Why?
|
| Gelatinases | 1 | 2007 | 53 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1563 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2007 | 118 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 703 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2008 | 220 | 0.020 |
Why?
|
| Adipocytes | 1 | 2009 | 299 | 0.020 |
Why?
|
| Catalysis | 1 | 2007 | 245 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 2033 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 164 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2170 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 239 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 206 | 0.020 |
Why?
|
| Lung | 2 | 2009 | 3298 | 0.020 |
Why?
|
| Uterine Diseases | 1 | 2006 | 38 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 581 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 694 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2009 | 440 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2007 | 230 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2007 | 354 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2006 | 78 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2006 | 178 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2006 | 284 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 121 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 4895 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 467 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 5338 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 387 | 0.020 |
Why?
|
| Edema | 1 | 2006 | 262 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 589 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 484 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2007 | 1254 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2008 | 464 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6224 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2009 | 997 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 2422 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 10265 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2007 | 1309 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 3028 | 0.010 |
Why?
|
| Macrophages | 1 | 2008 | 1350 | 0.010 |
Why?
|
| Peptides | 1 | 2007 | 1504 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 3438 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2002 | 243 | 0.010 |
Why?
|
| Fluorescence | 1 | 2002 | 198 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2002 | 167 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 603 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 4567 | 0.010 |
Why?
|
| Light | 1 | 2002 | 279 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 13006 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2023 | 39890 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6685 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 5002 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5694 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 1060 | 0.010 |
Why?
|
| Leukemia | 1 | 2008 | 1719 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 2518 | 0.010 |
Why?
|